Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth Corp. (Nasdaq: DRIO) announced new research demonstrating that its digital health solutions effectively improve glycemic control in rural residents with Type 2 diabetes, similar to outcomes seen in urban populations. The study, presented at the ADCES Annual Conference, revealed significant reductions in average blood glucose levels over 12 months for both groups. This suggests that Dario's platform can address healthcare challenges faced by rural communities, potentially enhancing access to effective chronic condition management.
DarioHealth Corp. (NASDAQ: DRIO) will announce its financial results for Q2 2022 on August 15, 2022, at 8:30 am ET. The announcement will be followed by a conference call hosted by CEO Erez Raphael, President Rick Anderson, and CFO Zvi Ben-David. Participants should dial in 10 minutes early to the numbers provided. A replay will be available shortly after the event until September 15, 2022. DarioHealth provides digital health solutions for chronic conditions, aiming to enhance patient management through personalized interventions and data analytics.
DarioHealth Corp. (Nasdaq: DRIO) presented new research at the American Psychological Association Annual Convention on August 4-6, 2022, highlighting its digital behavioral health solution's effectiveness. Findings revealed that 72% of users with clinically elevated depression symptoms saw a reduction over 12 weeks, while 44% experienced significant improvements. Additionally, 68% of users with moderate to severe anxiety reported improvements, with 40% achieving clinically significant reductions. The studies emphasize Dario's integrated approach, associating better health outcomes for individuals with chronic conditions.
Summary not available.
Summary not available.
Solera Health announces a partnership with DarioHealth to enhance hypertension management solutions. This collaboration introduces a streamlined system for payers and employers to access Dario's digital therapeutics, promoting a comprehensive approach to chronic conditions.
Dario's solution includes a connected blood pressure monitor and a smart app, supporting user engagement through personalized coaching. The CDC reports nearly half of U.S. adults have high blood pressure, contributing to $198 billion in healthcare costs annually. This partnership aims to improve patient outcomes and reduce related costs.
DarioHealth Corp. (NASDAQ: DRIO) has secured a $50 million senior secured term loan facility from OrbiMed, enhancing its financial stability. The initial $25 million is available immediately, with another $25 million contingent on achieving revenue thresholds by June 30, 2023. This funding aims to support DarioHealth's digital therapeutics platform, especially in chronic disease management. The company now potentially has over $100 million in capital access, allowing it to invest in its growing B2B market segment without needing further capital raises.
DarioHealth Corp. (Nasdaq: DRIO) highlighted breakthroughs in chronic condition management at the American Diabetes Association's 82nd Scientific Sessions on June 3-7, 2022. Three studies revealed significant enhancements in glucose control and reductions in blood pressure for users facing diabetes and hypertension. Key findings include:
- Two-thirds of users improved systolic blood pressure by 13 mmHg.
- High-risk Type 2 diabetes users reduced blood glucose by 15%.
- Average blood glucose decreased by 14%-15% across diverse ethnicities.
The integrated solutions demonstrate Dario's potential to transform chronic condition management.
DarioHealth Corp. (NASDAQ: DRIO) announced two new contracts to provide digital therapeutic solutions to a national employer and a provider group, effective Q3 2022. The Texas-based employer will implement digital behavioral health support for employees across 17 states, while the provider group will utilize Dario's integrated metabolic solutions for diabetes and weight management. These contracts are expected to enhance Dario's revenue growth in 2022, aligning with their strategy to expand their client base and personalized health solutions.
DarioHealth Corp. (Nasdaq: DRIO) reported a strong Q1 2022, posting revenues of $8.06 million, a 124% increase year-over-year and a 34% rise sequentially. Gross margins expanded to 49.4% (GAAP) and 61% (non-GAAP). The company added 14 new B2B accounts, including two health plans, and secured a $30 million agreement with Sanofi to enhance its market outreach. Despite an operating loss of $15.9 million, DarioHealth improved its financial position by reducing operating costs and marketing expenses, indicating a positive trend in its B2B transformation.